Investors never know what to expect for LCA-Vision
What analysts say:
- Buy, sell, or hold?: Analysts don't like LCA-Vision as much as competitor Hanger Orthopedic Group overall. Four out of four analysts rate Hanger Orthopedic Group a buy compared to zero of one for LCA-Vision. LCA-Vision's rating hasn't changed over the past three months.
- Revenue Forecasts: On average, analysts predict $22.5 million in revenue this quarter. That would represent a rise of 16.8% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is a loss of $0.10 per share.
What our community says:
CAPS All-Stars are strongly backing the stock, with 95.3% awarding it an "outperform" rating. The community at large concurs with the All-Stars, with 90.5% granting it a rating of "outperform." Fools feel positively about LCA-Vision and haven't been shy with their opinions lately, logging 219 posts in the past 30 days. Despite the majority sentiment in favor of LCA-Vision, the stock has a middling CAPS rating of three out of five stars.
Management:
Now let's look at how efficient management is at running the business. Margins illustrate how efficiently a company captures portions of sales dollars. LCA-Vision has seen increasing operating margins year-over-year for the last four quarters. Operating margins reflect the total sales revenue that the company retains after costs. Here is how LCA-Vision has been doing for the last four quarters:
Quarter | Q3 | Q2 | Q1 | Q4 |
Gross Margin | 28.2% | 32.3% | 41.1% | 27.3% |
Operating Margin | (18.8%) | (11.3%) | 6.1% | (38.3%) |
Net Margin | (17.4%) | (11.3%) | 6.3% | (37.8%) |
One final thing: If you want to keep tabs on LCA-Vision movements, and for more analysis on the company, make sure you add it to your Watchlist.